Marketing of personalized cancer care on the web: an analysis of Internet websites.

Stacy W Gray, Angel Cronin, Elizabeth Bair, Neal Lindeman, Vish Viswanath, Katherine A Janeway

Abstract read

In one paragraph

Article in Journal of the National Cancer Institute, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it

0cells of the map it votes in

8citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

Personalized Cancer Medicine in the Media: Sensationalism or Realistic Reporting?Journal of personalized medicine · 2021
Article
From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2018
Article
Palliative care content on cancer center websites.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018
Article
Medical Oncologists' Experiences in Using Genomic Testing for Lung and Colorectal Cancer Care.Journal of oncology practice · 2017
Article
Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2017
Article
Pediatric Oncology Provider Views on Performing a Biopsy of Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling.Annals of surgical oncology · 2016
Article
Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine.Oncotarget · 2016
Review
Breast cancer multigene testing trends and impact on chemotherapy use.The American journal of managed care · 2016
Article

4 · The record

Corrections and comments

Commented on by
Online marketing of personalised cancer tests discusses benefits more than limitations, study shows.2015

5 · Who and what money

Authors and funding

6 authors.

Stacy W GrayDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (SWG, AC, EB, VV); Harvard Medical School, Boston, MA (SWG, NL, KAJ); Department of Medicine, Brigham and Women's Hospital, Boston, MA (SWG, NL); Harvard School of Public Health, Boston, MA (VV); Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA (KAJ); Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA (KAJ). stacyw_gray@dfci.harvard.edu.

Angel CroninDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (SWG, AC, EB, VV); Harvard Medical School, Boston, MA (SWG, NL, KAJ); Department of Medicine, Brigham and Women's Hospital, Boston, MA (SWG, NL); Harvard School of Public Health, Boston, MA (VV); Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA (KAJ); Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA (KAJ).

Elizabeth BairDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (SWG, AC, EB, VV); Harvard Medical School, Boston, MA (SWG, NL, KAJ); Department of Medicine, Brigham and Women's Hospital, Boston, MA (SWG, NL); Harvard School of Public Health, Boston, MA (VV); Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA (KAJ); Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA (KAJ).

Neal LindemanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (SWG, AC, EB, VV); Harvard Medical School, Boston, MA (SWG, NL, KAJ); Department of Medicine, Brigham and Women's Hospital, Boston, MA (SWG, NL); Harvard School of Public Health, Boston, MA (VV); Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA (KAJ); Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA (KAJ).

Vish ViswanathDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (SWG, AC, EB, VV); Harvard Medical School, Boston, MA (SWG, NL, KAJ); Department of Medicine, Brigham and Women's Hospital, Boston, MA (SWG, NL); Harvard School of Public Health, Boston, MA (VV); Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA (KAJ); Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA (KAJ).

Katherine A JanewayDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (SWG, AC, EB, VV); Harvard Medical School, Boston, MA (SWG, NL, KAJ); Department of Medicine, Brigham and Women's Hospital, Boston, MA (SWG, NL); Harvard School of Public Health, Boston, MA (VV); Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA (KAJ); Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA (KAJ).

Funding

The Use of Whole-Exome Sequencing to Guide the Care of Cancer PatientsU01HG006492 · NHGRI · DANA-FARBER CANCER INST · PI JANNE, PASI A, VAN ALLEN, ELIEZER M · 2012 to 2016

$7.3M

NHGRI NIH HHS U01 HG006492NHGRI NIH HHS U01HG006492

6 · The paper itself

Abstract

Internet marketing may accelerate the use of care based on genomic or tumor-derived data. However, online marketing may be detrimental if it endorses products of unproven benefit. We conducted an analysis of Internet websites to identify personalized cancer medicine (PCM) products and claims. A Delphi Panel categorized PCM as standard or nonstandard based on evidence of clinical utility. Fifty-five websites, sponsored by commercial entities, academic institutions, physicians, research institutes, and organizations, that marketed PCM included somatic (58%) and germline (20%) analysis, interpretive services (15%), and physicians/institutions offering personalized care (44%). Of 32 sites offering somatic analysis, 56% included specific test information (range 1-152 tests). All statistical tests were two-sided, and comparisons of website content were conducted using McNemar's test. More websites contained information about the benefits than limitations of PCM (85% vs 27%, P < .001). Websites specifying somatic analysis were statistically significantly more likely to market one or more nonstandard tests as compared with standard tests (88% vs 44%, P = .04).

Indexed as

DNA Mutational AnalysisGenetic TestingInternetMarketing of Health ServicesPrecision MedicineHumansNeoplasmsUnited StatesUnited States Food and Drug Administration

Identifiers

PMID25745021

DOI10.1093/jnci/djv030

PMCPMC4822521

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.